Guardant Health R&D decreased by 7.4% to $91.04M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.8%, from $88.52M to $91.04M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 8.5% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2016
Last reportedQ1 2026May 7, 2026
How to read this metric
Higher spending signals a robust pipeline and future growth potential, though it may temporarily depress current profitability.
Detailed definition
Research and development expenses represent investments in the discovery, clinical validation, and regulatory approval o...
Peer comparison
High in biotech/diagnostics; peers often spend a significant percentage of revenue on R&D to maintain competitive advantage.
Metric ID:
research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $63.72M | $70.97M | $73.02M | $81.76M | $85.46M | $100.02M | $106.58M | $93.13M | $90.36M | $93.85M | $89.86M | $83.8M | $83.1M | $87.31M | $93.54M | $88.52M | $87.45M | $89.96M | $98.26M | $91.04M |
| QoQ Change | — | +11.4% | +2.9% | +12.0% | +4.5% | +17.0% | +6.6% | -12.6% | -3.0% | +3.9% | -4.3% | -6.7% | -0.8% | +5.1% | +7.1% | -5.4% | -1.2% | +2.9% | +9.2% | -7.4% |
| YoY Change | — | — | — | — | +34.1% | +40.9% | +46.0% | +13.9% | +5.7% | -6.2% | -15.7% | -10.0% | -8.0% | -7.0% | +4.1% | +5.6% | +5.2% | +3.0% | +5.0% | +2.8% |
Range$63.72M – $106.58M
CAGR+7.8%
Avg YoY Growth+7.5%
Median YoY Growth+4.6%
R&D at Other Companies
Frequently Asked Questions
- What is Guardant Health's r&d?
- Guardant Health (GH) reported r&d of $91.04M in Q1 2026.
- How has Guardant Health's r&d changed year-over-year?
- Guardant Health's r&d increased by 2.8% year-over-year, from $88.52M to $91.04M.
- What is the long-term trend for Guardant Health's r&d?
- Over 4 years (2021 to 2025), Guardant Health's r&d has grown at a 8.5% compound annual growth rate (CAGR), from $263.22M to $364.19M.
- What does r&d mean?
- Spending dedicated to creating new products or improving existing technology.